BioSpace News Archive

Biofrontera Inc. (Nasdaq:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that it will report financial results for the three months ended March 31, 2023 on Friday, May 12, 2023.

Aptorum Group Limited announced financial results for the fiscal year ended December 31, 2022, and provided an update on clinical and corporate developments.

Castle Biosciences, Inc. today announced that it has teamed up with IMPACT Melanoma, one of the nation’s leading non-profit organizations dedicated to melanoma prevention and early detection, as sunscreen sponsors of the Bike MS: Texas MS 150 2023 event, being held April 29-30 in Texas.

Apyx Medical Corporation Receives FDA 510(k) Clearance for the Use of Renuvion ® for Coagulation of Subcutaneous Soft Tissues Following Liposuction for Aesthetic Body Contouring.

Intuitive (NASDAQ: ISRG), a global technology leader in minimally invasive care and pioneer of robotic-assisted surgery, announced that the Food and Drug Administration recently cleared the da Vinci SP surgical system for simple prostatectomy as a representative procedure, which expands the urologic surgical procedures cleared by FDA.

Kala Pharmaceuticals, Inc. announced that the California Institute for Regenerative Medicine has awarded Combangio, Inc., a wholly owned subsidiary of Kala, a $15 million grant to support its ongoing KPI-012 program for the treatment of persistent corneal epithelial defect.

Genetic Technologies Limited is pleased to announce the publication of a research paper in the peer-reviewed journal Melanoma Research validating the geneType for Melanoma risk assessment test in one of the most commonly diagnosed cancers in the Western world, 3rd in Australia and 5th in the United States.

INOVIO today announced that first quarter 2023 financial results will be released after the market close on May 10, 2023.

RaySearch Laboratories AB publishes its Annual Report for the financial year 2022.

Hemogenyx Pharmaceuticals plc, the biopharmaceutical group developing new therapies and treatments for deadly blood diseases, announces its results for the year ended 31 December 2022.